Psound Bytes CME

About Psound Bytes CME

National Psoriasis Foundation presents Psound Bytes Pro, a podcast series featuring leading experts discussing recognizing, diagnosing, and managing psoriasis and/or psoriatic arthritis. Listen to world-renowned dermatologists and rheumatologists discuss the latest news in psoriatic disease management.

Publisher

National Psoriasis Foundation

Category

education · health & fitness

Language

en

Explicit

No

First episode

7 Jan 2019

Latest episode

19 Aug 2026

Latest episodes

102 episodes in the feed.

1. 

   19 Aug 2026

   Ep. #201 "Advancing Early Detection: A Multi-Omic Test for Psoriatic Arthritis"

   In this episode, rheumatologist and clinician-scientist Dr. Vinod Chandran discusses his research into a diagnostic test for psoriatic arthritis with NPF CSMO Dr. Guy Eakin. Key learnings: Early diagnosis of psoriatic arthritis (PsA) is critical for better outcomes. PsA is often difficult to recognize because symptoms vary widely and can resemble common age-related joint or back pain. Earlier identification and treatment can reduce joint damage, improve quality of life, lower chronic pain burden, and potentially decrease cardiovascular and mental health complications. The heterogeneity of PsA makes developing a diagnostic test especially challenging. PsA presents differently across patients, sexes, ethnic groups, and stages of disease. Some patients develop arthritis after psoriasis, while others may develop it before or even without obvious psoriasis, making a single broadly applicable diagnostic test difficult to create. A multi-omic approach shows promise for distinguishing PsA from psoriasis alone. Dr. Chandran's team evaluated multiple biological data sources, including gene expression, microRNAs, proteins, and metabolites. Their research identified a signature of approximately 200 markers that could differentiate patients with PsA from those with psoriasis only, demonstrating the feasibility of a biomarker-based diagnostic test. The future of precision medicine in psoriatic disease depends on reliable biomarkers. Beyond diagnosis, biomarkers could help predict disease severity, guide treatment selection, and improve long-term outcomes by identifying the right therapy for the right patient at the right time. Achieving this will require continued collaboration, validation across diverse populations, and development of clinically practical, cost-effective tests. Looking for more information related to his research? Read more about the NPF PsA Diagnostic Test Grant outcomes: https://www.psoriasis.org/advance/psoriatic-arthritis-diagnostic-test-grant/ This publication is supported by the Centers for Disease Control and Prevention of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $375,000 with 100 percent funded by CDC/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by CDC/HHS, or the U.S. Government.

2. 

   25 Jun 2026

   Ep. #200 "Improving outcomes: Addressing obesity and inflammation in psoriasis"

   Hear from dermatologist Dr. Ron Prussick and cardiologist Dr. Brittany Weber as they discuss the emerging role of GLP-1 receptor agonists in the management of patients with psoriasis. This conversation explores the intersection of psoriatic disease, obesity, and cardiometabolic health, and how these therapies may support improved outcomes. Learn more about the National Psoriasis Foundation's GLP-1 Primer for Dermatologists: https://www.psoriasis.org/glp-1-primer-for-dermatologists/ Key Takeaways Patients with higher BMI have a lower likelihood of achieving PASI 90 and 100 and a higher risk of developing PsA and other comorbidities. Psoriasis is linked to increased cardiovascular risk, and GLP-1 therapies can address multiple drivers at once, including adiposity, cardiometabolic dysfunction, and inflammatory burden. Patients with psoriasis or psoriatic arthritis who also have metabolic comorbidities such as obesity, insulin resistance, fatty liver disease, or diabetes, as well as related conditions like hidradenitis suppurativa, may be strong candidates for adding GLP-1 agonists alongside standard psoriasis therapies. This podcast is supported in part by Lilly.

3. 

   5 Feb 2026

   Ep. 199 "TB Testing in the Era of IL‑17 and IL‑23 Inhibitors"

   In this episode, Dr. Andrew Blauvelt and Dr. G. Scott Drew talk with NPF CSMO Dr. Guy Eakin about when—and whether—TB testing is needed before initiating psoriasis therapies. Listeners can read the NPF/IPC position paper referenced here: https://www.jaad.org/article/S0190-9622(25)03232-3/fulltext Key Takeaways: 1. Data show that the progression from latent tuberculosis infection to active disease during psoriasis treatment with IL-17 or IL-23 is rare. 2. TB testing may still be appropriate for specific patients and in certain clinical conditions. 3. Updated NPF and IPC joint position statement, published in JAAD, aims to drive practice change. This podcast is supported by the Centers for Disease Control and Prevention of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $375,000 with 100 percent funded by CDC/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by CDC/HHS, or the U.S. Government.

Who has been a guest on Psound Bytes CME

Names identified in recent episode analyses. Showing up to five guests.

• Dr Mark Lebwohl
• Dr Jason Hawkes
• Dr. Bruce Strober, MD, PhD
• Guy Eakin, PhD

Reach and audience

Public platform figures. Ratings count people who left a rating, not total listeners.

Apple Podcasts (US)

4.5 / 5

8 ratings

Spotify

5.0 / 5

2 ratings

Podcast Authority Score: 44 / 100

A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.

Quality

61

Social presence

0

YouTube

0

Engagement

68

Contact Psound Bytes CME

Guest appearances

Books guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.